Skip to main content

Table 4 Postoperative complications and adverse events

From: Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study

  Total (n = 38)
Postoperative complications
Nausea 11 (28.9%)
Pain 11 (28.9%)
Vomiting 3 (7.9%)
Fever 4 (10.5%)
Adverse events
Grade 3–4 adverse events 7 (18.4%)
Hand-foot syndrome 8 (21.1%)
Anemia 4 (10.5%)
Leukopenia 4 (10.5%)
Thrombocytopenia 5 (13.2%)
Elevated aspartate transaminase 4 (10.5%)
Hyperbilirubinemia 2 (5.3%)
Diarrhea 4 (10.5%)
Nausea 1 (2.6%)
Hypertension 2 (5.3%)
Rash 2 (5.3%)